<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>NL-KVK-34185938-Access to Medicine Index FY22</iati-identifier>
  <reporting-org ref="NL-KVK-34185938" type="60">
   <narrative xml:lang="EN">Access to Medicine Foundation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Access to Medicine Index FY22</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">The Access to Medicine Index analyses 20 of the world&#x2019;s largest research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries. This activity files includes the 2021 activities.</narrative>
  </description>
  <participating-org activity-id="Not Available" role="1" type="70">
   <narrative xml:lang="EN">AXA Investment Managers</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-DAC-1601" role="1" type="60">
   <narrative xml:lang="EN">Bill and Melinda Gates Foundation</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-7" role="1" type="10">
   <narrative xml:lang="EN">Netherlands - Ministry of Foreign Affairs</narrative>
  </participating-org>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">The Leona M. &amp; Harry B. Helmsley Charitable Trust</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-1" role="1" type="10">
   <narrative xml:lang="EN">UK - Foreign, Commonwealth and Development Office</narrative>
  </participating-org>
  <participating-org activity-id="Not available" role="1" type="60">
   <narrative xml:lang="EN">Wellcome Trust</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2022-01-01" type="2"></activity-date>
  <activity-date iso-date="2022-12-31" type="3"></activity-date>
  <recipient-country code="NL" percentage="100">
   <narrative xml:lang="EN">The Access to Medicine Index will measure pharmaceutical companies&apos; efforts to improve access to medicine across 106 low- and middle-income countries. The Access to Medicine Index team is based in The Netherlands.</narrative>
  </recipient-country>
  <sector code="12220" percentage="100" vocabulary="1"></sector>
  <budget status="2" type="1">
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-31"></period-end>
   <value currency="EUR" value-date="2022-01-01">2738435</value>
  </budget>
  <transaction humanitarian="0" ref="AXA IM 2022 instalment">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-06-17"></transaction-date>
   <value currency="EUR" value-date="2022-06-17">250000</value>
   <description>
    <narrative xml:lang="EN">2022 instalment AXA IM</narrative>
   </description>
  </transaction>
  <transaction ref="BMGF instalment">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-17"></transaction-date>
   <value currency="USD" value-date="2022-03-17">525721</value>
   <description>
    <narrative xml:lang="EN">2022 instalment BMGF.</narrative>
   </description>
   <provider-org ref="XM-DAC-DAC-1601"></provider-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="EUR" value-date="2022-01-01">2738435</value>
   <description>
    <narrative xml:lang="EN">ATMF commitment to spend on ATMI.</narrative>
   </description>
  </transaction>
  <transaction ref="AXA-IM - deferred">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="EUR" value-date="2022-01-01">100000</value>
   <description>
    <narrative xml:lang="EN">Deferred income from AXA-IM.</narrative>
   </description>
  </transaction>
  <transaction ref="BMGF - deferred">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="USD" value-date="2022-01-01">563153</value>
   <description>
    <narrative xml:lang="EN">Deferred income from BMGF.</narrative>
   </description>
   <provider-org ref="XM-DAC-DAC-1601"></provider-org>
  </transaction>
  <transaction ref="FCDO - deferred">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="GBP" value-date="2022-01-01">336340</value>
   <description>
    <narrative xml:lang="EN">Deferred income from FCDO-UK (former DFID).</narrative>
   </description>
   <provider-org ref="GB-GOV-1"></provider-org>
  </transaction>
  <transaction ref="MinBuza - deferred">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="EUR" value-date="2022-01-01">300000</value>
   <description>
    <narrative xml:lang="EN">Deferred income from MinBuza.</narrative>
   </description>
  </transaction>
  <transaction ref="Helmsley - deferred">
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="USD" value-date="2022-01-01">312500</value>
   <description>
    <narrative xml:lang="EN">Deferred income from The Leona M.&amp; Harry B. Helmsley Charitable Trust.</narrative>
   </description>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2022-06-30"></transaction-date>
   <value currency="EUR" value-date="2022-06-30">904549</value>
   <description>
    <narrative xml:lang="EN">Employee, depreciation, travel, housing, consultants and supply expenses for the period 1 Jan 2022 - 30 Jun 2022</narrative>
   </description>
  </transaction>
  <transaction ref="Helmsley">
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="USD" value-date="2022-01-01">312500</value>
   <description>
    <narrative xml:lang="EN">Part of grant agreement with The Leona M. &amp; Harry B. Helmsley Charitable Trust allocated to FY22.</narrative>
   </description>
  </transaction>
  <transaction ref="AXA IM">
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="EUR" value-date="2022-01-01">300000</value>
   <description>
    <narrative xml:lang="EN">Part of the grant agreement with AXA IM allocated to FY22</narrative>
   </description>
  </transaction>
  <transaction ref="BMGF">
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="USD" value-date="2022-01-01">676410</value>
   <description>
    <narrative xml:lang="EN">Part of the grant agreement with BMGF allocated to FY22.</narrative>
   </description>
   <provider-org ref="XM-DAC-DAC-1601"></provider-org>
  </transaction>
  <transaction ref="FCDO-UK">
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="GBP" value-date="2022-01-01">428696</value>
   <description>
    <narrative xml:lang="EN">Part of the grant agreement with FCDO-UK (former DFID) allocated to FY22.</narrative>
   </description>
   <provider-org ref="GB-GOV-1"></provider-org>
  </transaction>
  <transaction ref="MinBuza">
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="EUR" value-date="2022-01-01">875000</value>
   <description>
    <narrative xml:lang="EN">Part of the grant agreement with MinBuza allocated to FY22.</narrative>
   </description>
   <provider-org provider-activity-id="XM-DAC-PPR-4000001257" ref="XM-DAC-7"></provider-org>
  </transaction>
  <transaction ref="Wellcome Trust">
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2022-01-01"></transaction-date>
   <value currency="EUR" value-date="2022-01-01">119967</value>
   <description>
    <narrative xml:lang="EN">Part of the grant agreement with Wellcome Trust allocated to FY22</narrative>
   </description>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/amsterdam-session-on-global-health-security-meeting-report">
   <title>
    <narrative xml:lang="EN">Amsterdam Session on Global Health Security Meeting Report</narrative>
   </title>
   <category code="A02"></category>
   <language code="EN"></language>
   <document-date iso-date="2022-03-01"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/spotlight-on-pharmaceutical-companies-actions-in-womens-health-and-srhr">
   <title>
    <narrative xml:lang="EN">Spotlight on pharmaceutical companies&#x2019; actions in women&#x2019;s health and SRHR</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Ahead of a special report in the 2022 Access to Medicine Index, the Foundation has published a Briefing on key issues in women&apos;s health and SRHR (sexual and reproductive health and rights), and the role of pharmaceutical companies in making sure essential health products are available and accessible to women in low- and middle-income countries (LMICs).</narrative>
   </description>
   <category code="A08"></category>
   <language code="EN"></language>
   <document-date iso-date="2022-05-25"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/workshop-on-expanding-access-to-generic-medicine-meeting-report-1">
   <title>
    <narrative xml:lang="EN">Workshop on Expanding Access to Generic Medicine &#x2013; Meeting Report</narrative>
   </title>
   <category code="A08"></category>
   <language code="EN"></language>
   <document-date iso-date="2022-05-12"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/2021-annual-report-of-the-access-to-medicine-foundation">
   <title>
    <narrative xml:lang="EN">2021 Annual Report of the Access to Medicine Foundation</narrative>
   </title>
   <category code="B01"></category>
   <language code="EN"></language>
   <document-date iso-date="2022-03-31"></document-date>
  </document-link>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Writing and publishing the Spotlight on pharmaceutical companies&#x2019; actions in women&#x2019;s health and SRHR</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Ahead of a special report in the 2022 Access to Medicine Index, the Foundation has published a Briefing on key issues in women&apos;s health and SRHR (sexual and reproductive health and rights), and the role of pharmaceutical companies in making sure essential health products are available and accessible to women in low- and middle-income countries (LMICs).</narrative>
   </description>
   <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/spotlight-on-pharmaceutical-companies-actions-in-womens-health-and-srhr">
    <title>
     <narrative xml:lang="EN">Ahead of a special report in the 2022 Access to Medicine Index, the Foundation has published a Briefing on key issues in women&apos;s health and SRHR (sexual and reproductive health and rights), and the role of pharmaceutical companies in making sure essential health products are available and accessible to women in low- and middle-income countries (LMICs).</narrative>
    </title>
    <category code="A08"></category>
    <document-date iso-date="2022-06-27"></document-date>
   </document-link>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">https://accesstomedicinefoundation.org/publications/spotlight-on-pharmaceutical-companies-actions-in-womens-health-and-srhr</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">Ahead of a special report in the 2022 Access to Medicine Index, the Foundation has published a Briefing on key issues in women&apos;s health and SRHR (sexual and reproductive health and rights), and the role of pharmaceutical companies in making sure essential health products are available and accessible to women in low- and middle-income countries (LMICs).</narrative>
    </description>
    <period>
     <period-start iso-date="2022-05-25"></period-start>
     <period-end iso-date="2022-05-25"></period-end>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Writing and publication of the workshop on Expanding Access to Generic Medicine meeting report</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">On 6 April 2022, the Access to Medicine Foundation convened a virtual workshop to identify solutions for strengthening the global supply of essential medicine and vaccines. The summary of the discussion has been captured in a meeting report, which is now available for download.</narrative>
   </description>
   <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/workshop-on-expanding-access-to-generic-medicine-meeting-report-1">
    <title>
     <narrative xml:lang="EN">On 6 April 2022, the Access to Medicine Foundation convened a virtual workshop to identify solutions for strengthening the global supply of essential medicine and vaccines. The summary of the discussion has been captured in a meeting report, which is now available for download.</narrative>
    </title>
    <category code="A08"></category>
    <document-date iso-date="2022-05-12"></document-date>
   </document-link>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Workshop on Expanding Access to Generic Medicine &#x2013; Meeting Report</narrative>
    </title>
    <period>
     <period-start iso-date="2022-05-12"></period-start>
     <period-end iso-date="2022-05-12"></period-end>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Writing and publication for AMR Thematic study: Lack of access to medicine is a major driver of drug resistance. How can pharma take action?</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">The antibiotic market is unstable, with fragile supply chains and tough market conditions. This report sets out how these factors limit the development of a robust go-to-market model for such products. It features six case studies where companies and their partners are using a combination of access strategies to cut through the complexity and address access at a local level.</narrative>
   </description>
   <document-link format="APPLICATION/PDF" url="https://accesstomedicinefoundation.org/publications/lack-of-access-to-medicine-is-a-major-driver-of-drug-resistance-how-can-pharma-take-action-1">
    <title>
     <narrative xml:lang="EN">Lack of access to medicine is a major driver of drug resistance. How can pharma take action?</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">https://accesstomedicinefoundation.org/publications/lack-of-access-to-medicine-is-a-major-driver-of-drug-resistance-how-can-pharma-take-action-1</narrative>
    </description>
    <category code="A08"></category>
    <language code="EN"></language>
    <document-date iso-date="2022-06-09"></document-date>
   </document-link>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Lack of access to medicine is a major driver of drug resistance. How can pharma take action?</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">The antibiotic market is unstable, with fragile supply chains and tough market conditions. This report sets out how these factors limit the development of a robust go-to-market model for such products. It features six case studies where companies and their partners are using a combination of access strategies to cut through the complexity and address access at a local level.</narrative>
    </description>
    <period>
     <period-start iso-date="2022-06-09"></period-start>
     <period-end iso-date="2022-06-09"></period-end>
    </period>
   </indicator>
  </result>
  <result aggregation-status="1" type="1">
   <title>
    <narrative xml:lang="EN">Writing and publication of the 2021 Annual Report of the Access to Medicine Foundation</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Writing and publication of the 2021 Annual Report of the Access to Medicine Foundation</narrative>
   </description>
   <indicator aggregation-status="1" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">Writing and publication of the 2021 Annual Report of the Access to Medicine Foundation</narrative>
    </title>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2022-03-30"></period-end>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">Writing and publication of the Amsterdam Session on Global Health Security Meeting Report</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Writing and publication of the Amsterdam Session on Global Health Security Meeting Report</narrative>
   </description>
   <indicator measure="1">
    <title>
     <narrative xml:lang="EN">Writing and publication of the Amsterdam Session on Global Health Security Meeting Report</narrative>
    </title>
    <period>
     <period-start iso-date="2022-02-03"></period-start>
     <period-end iso-date="2022-03-01"></period-end>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
